1Panunti B, Kunhiraman B, Fonseca V, et al. The impact of antidiabetic therapies on cardiovascular disease. Curr Atheroscler Rep, 2005; 7(1):50- 57
2Malerod L,Sporstol M,Juvet LK,et al.. Hepatic scavenger receptor class B, type Ⅰ is stimulated by peroxisome proliferator - activated receptor gamma and hepatocyte nuclear factor 4alpha. Biochem - BiophysRes - Commun,2003;305(3): 557- 565
3Matsuda M, Shimoura I, Sata M, et al. Role of adiponectin in reventing vascular stenosis the missing link of adipo vascular axis .J Biol Chem,2002; 277: 37487 - 37491
4Sugawara A, Takeuchi A, Uruno A, et al.Transcriptional suppression of type 1 angiotension Ⅱ receptor gene expression by peroxsome proliferators activated receptor gamma invascular smmoth musclec cells[J] . Endocrinology,2001; 142:3125-3134
5Combs TP, WangnerJA, BergerJ , et al. Induction ofadpocyte complement - releated protein of 30 kilo daltons by PPAR agonists: Apotential mechanism of insulin sensitization . Endocrinology, 2002; 143: 998-1007
7Nordt TK, Peter K, Bode C, et al. Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells .J Clin Endocinol Metab,2000;85: 1563- 1568
8Goetze S, Bungenstock A, Czupallla C, et al. Leptin indces endothelia cell migration through Akt, which is inhibited by PPAR gamma ligands [J]Hypertension, 2002; 40(5):748-754
9Gllis T,Mo QZ,Liu HR,et al. Anti - apoptotic effect of the PPAR gamma agonsit Rosiglitazone aortic endothelial cells in hypercholesterole mic rabbits[J] .Acad Emerg Med,2003; 10(5) :558
10Artwohl M, Furnsinn C, Waldhausl W, et al.Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma- independent mechanism. Diabetologia, 2005;48(3) :586- 594
